Objective-To determine whether the administration of an active form of vitamin D 3 (calcitriol) could prevent atherosclerosis through anti-inflammatory actions. Methods and Results-Recent clinical studies have shown that lack of vitamin D 3 is a risk factor for cardiovascular events.
D 3 , is a secosteroid hormone that not only plays a central role in bone and calcium metabolism but also modulates the immune response. Recent epidemiological studies have shown a relationship between low plasma levels of vitamin D 3 and a predisposition to cardiovascular events. [1] [2] [3] This finding is supported by a meta-analysis showing that oral vitamin D 3 treatment contributes to the improvement of mortality from all causes, in part by decreasing cardiovascular deaths. 4 Transgenic rats constitutively expressing vitamin D-24-hydroxylase, a model of vitamin D 3 deficiency, showed aggravated atherosclerosis under a high-fat and high-cholesterol diet, when compared with control rats. 5 However, there are no reports about the direct effects of an orally administered active form of vitamin D 3 on atherosclerosis.
See accompanying article on page 2317
It is widely recognized that atherosclerosis is a complex inflammatory disease of the arterial wall, 6, 7 in which the T-lymphocyte-mediated pathogenic immune response plays a critical role. Clinical strategies developed to modulate the immune response have been insufficient for preventing atherosclerosis. Cumulative data based on experimental animal models suggest that CD4 ϩ T cells are present within plaques from the initial stages of the disease in mice, and adaptive transfer of these cells is potentially proatherogenic. 8 Accumulating evidence has revealed novel functions of several subsets of regulatory T cells (Tregs), which maintain immunologic tolerance to self-antigens and inhibit atherosclerosis development by suppressing the inflammatory response of effector T cells. 9 -12 These studies have provided new insights into the immunopathogenesis of atherosclerosis and imply that promotion of regulatory immune responses may have therapeutic potential for suppression of atherosclerotic diseases.
In addition to Tregs, dendritic cells (DCs) are also reportedly involved in maintaining immune tolerance to self-antigens. DCs are the most potent antigen-presenting cells. They efficiently stimulate the differentiation of effector T cells from naïve T-cell precursors. DCs are also thought to perform the important function of presenting antigens to T cells, which leads to peripheral tolerance by inducing Tregs or inhibiting effector T cells. 13 DCs can be tolerogenic and immunogenic. 14 In particular, immature DCs, which downregulate major histocompatibility complex class II molecules and costimulatory molecules (eg, CD40, CD80, and CD86) have had tolerogenic properties associated with decreased interleukin (IL) 12 and enhanced IL-10 production. Recently, the contribution of DCs to atherogenesis has been extensively examined. [15] [16] [17] Furthermore, DCs and Tregs may be helpful in inducing tolerance against self-antigens within plaques. Therefore, an agent able to modulate the function of DCs and Tregs may be beneficial in the treatment of atherosclerotic disease.
Recently, several articles have reported that 1,25(OH) 2dihydroxyvitamin D 3 induced reciprocal differentiation and/or expansion of Tregs and induced tolerogenic DCs characterized by downregulation of costimulatory molecules. 18 Calcitriol and its analogues have inhibited autoimmune disease, allergy, and the rejection of transplanted organs in animal models via induction of tolerogenic DCs and Tregs. 19 -21 However, the interaction between DCs and Tregs remains to be fully elucidated. Given this background, we examined whether orally administered calcitriol would induce Tregs and tolerogenic DCs in apolipoprotein E-knockout (ApoE Ϫ/Ϫ ) mice and how these immune cells might contribute to the inhibition of atherosclerosis. We focused not only on systemic immune responses but also on regulation of the intestinal immune system as therapeutic targets for suppressing the formation of atherosclerotic lesions. Our findings provide the first evidence that oral calcitriol administration induces Tregs and immature DCs via the intestinal immune system and that these 2 immune cells are induced both systemically and locally in atherosclerotic lesions, resulting in mutually suppressing pathogenic immune processes that play a pivotal role in the progression of atherosclerosis.
Methods
Detailed Methods are provided in the supplemental data (available online at http://atvb.ahajournals.org).
Experimental Design
We fed 6-week-old female ApoE Ϫ/Ϫ mice 20 or 200 ng of calcitriol dissolved in carboxymethylcellulose or vehicle alone by gastric intubation with a plastic tube twice a week for 12 weeks. Mice under the same protocol as previously described were injected with either 100 g of neutralizing CD25 monoclonal antibody (clone PC61) to deplete CD4 ϩ CD25 ϩ Tregs or 100 g of isotype-matched control rat IgG once every 4 weeks at the age of 6, 10, and 14 weeks. Mice were euthanized at the age of 18 weeks, and atherosclerotic lesions were examined as previously described. 12 All animal experiments were conducted according to the Guidelines for Animal Experiments at Kobe University School of Medicine, Kobe, Japan.
Cell Isolation Using In Vitro Cell Functional Experiments and Flow Cytometry Analyses
Purified CD4 ϩ T cells and CD11c ϩ DCs were isolated from mesenteric lymph nodes (MLNs) and spleens. A cell proliferation assay was performed by assessing [ 3 H]thymidine incorporation.
Fluorescence-activated cell sorter (FACS) analysis was performed. Total RNA was extracted from these cells for real-time RT-PCR.
Statistical Analysis
Data were expressed as meanϮSEM. To detect significant differences between 2 groups or among 3 groups, an unpaired Student t test, a Mann-Whitney U test, or a 1-way ANOVA with a post hoc test was used when appropriate. PϽ0.05 was considered statistically significant.
Results

Effects of Oral Calcitriol Treatment on General Conditions and Plasma Examination Values
Calcitriol at various doses inhibits autoimmune disease (0.03 g/kg PO per day), allergy (0.5 g/kg SC per day), and rejection of transplanted organs (5 g/kg PO 3 times per week) in animal models. 19 -21 Compared with previous reports, the dose used in our study (10 g/kg [200 ng] PO 2 times per week) was somewhat higher. However, severe adverse effects, such as loss in body weight and hypercalcemia, were not observed in the present study. Notably, 200 ng of calcitriol (2 times per week) significantly increased its plasma level without affecting plasma levels of 25(OH)hydroxyvitamin D 3 , intact parathyroid hormone, calcium, or phosphorus. Although plasma 25(OH)-hydroxyvitamin D 3 levels were inversely associated with renin activity in hypertensive patients, 2 and calcitriol administration led to suppression of renin in an animal model, 22 in the present study, calcitriol administration affected neither blood pressure nor renin mRNA expression in the kidney (Table) . The effect of vitamin D 3 supplementation on blood pressure may be limited only to subjects under hypertensive conditions or vitamin D 3 insufficiency. Contrary to our expectations, the administra- Figure 1 ).
Effects of Calcitriol on Tregs in the Small Intestine, MLNs, and Spleen
To investigate the effects of 200 ng of calcitriol treatment on Tregs in ApoE Ϫ/Ϫ mice, we performed immunohistochemical studies in the small intestine and flow cytometry analyses in MLNs and spleens. FACS analyses revealed that all of the Treg subsets, such as CD4 ϩ CD25 ϩ , CD4 ϩ CD25 ϩ Foxp3 ϩ , and CD4 ϩ Foxp3 ϩ , were significantly increased in the calcitriol group in MLNs and spleen (compared with the control group: PϽ0.05; Figure 2A -2D). A further detailed investigation just after starting calcitriol treatment revealed that the number of Tregs first increased in MLNs (but not thymus), suggesting that the active form of vitamin D 3 mainly induces Tregs peripherally (supplemental Figure I) . We also demonstrated a significant increase in intestinal Foxp3 ϩ Tregs by immunohistochemistry in the calcitriol group (PϽ0.05, Figure 2E ). Next, to confirm the induction of Tregs, we applied quantitative RT-PCR to assess mRNA levels of Tregassociated markers in CD4 ϩ T cells from MLNs after positively separating them with anti-CD4 ϩ microbeads (Figure 2F ). We found a significant increase in mRNA levels of Treg-associated markers (ie, CD25, Foxp3, and cytotoxic lymphocyte antigen 4 [CTLA4]) in the calcitriol group (PϽ0.05). In addition, mRNA expression of IL-10 and transforming growth factor (TGF)-␤ tended to increase in CD4 ϩ T cells from the MLNs of calcitriol-treated mice (Pϭ0.0816 and Pϭ0.510, respectively), suggesting the possibility of Treg induction. To determine whether a calcitriolinduced increase in Tregs contributes to the suppression of T-cell function, we performed in vitro proliferation assays of CD4 ϩ T cells from MLNs and spleen of the calcitriol or control group. As shown in Figure 2G , CD4 ϩ T-cell proliferation was suppressed in the calcitriol group, suggesting an increased number of Tregs by calcitriol might contribute to the suppressive potential of T lymphocytes.
Effects of Calcitriol on DCs in the Small Intestine, MLNs, and Spleen
CD80 and CD86 are recognized as important costimulatory molecules related to the maturation of DCs. We performed FACS analyses using MLN cells ( Figure 3A ) and splenocytes and found a significant decrease in CD80 ϩ CD86 ϩ mature DCs within the CD11c ϩ DC population from calcitrioltreated mice (PϽ0.05, Figure 3B ). To confirm the effects of calcitriol on inhibition of DC maturation, we assessed mRNA levels of DC-associated markers in CD11c ϩ DCs from spleens after positive selection with anti-CD11c ϩ microbeads ( Figure 3C ). RT-PCR analyses revealed that CD80 and CD86 mRNA levels tended to decrease in the calcitriol group (Pϭ0.098 and Pϭ0.1023, respectively). Furthermore, we found a significant decrease in IL-12p40 mRNA levels and an increase in those of IL-10 in the calcitriol group (PϽ0.05). Notably, we also found a significant increase in CC-chemokine ligand (CCL)17 and CCL22 mRNA levels, which were recognized as Treg-attracting chemokines, in the calcitriol group (PϽ0.05). Consistent with previous reports, 23, 24 these results indicate that calcitriol induced immature DCs, which interact with Tregs to suppress activation of immune reactions via their tolerogenic properties. To determine whether a calcitriol-induced increase in the number of tolerogenic DCs contributes to the suppression of T lymphocytes, we performed in vitro proliferation assays of CD4 ϩ T cells from Balb/c mouse spleens stimulated by CD11c ϩ DCs from the spleens of mice from the calcitriol or control group ( Figure 3D ). CD4 ϩ T-cell proliferation was suppressed to a greater extent when cocultured with DCs from the calcitriol group than when cultured with DCs from the control group. These results indicated that DCs from calcitriol-treated mice resulted in reduced proliferation activity of T lymphocytes. Taken together, tolerogenic DCs induced by oral calcitriol administration suppressed T-cell immune responses and worked as antiatherogenic factors mainly by changing their cytokine and chemokine productions. We further evaluated the number of CD11c ϩ CD86 ϩ mature DCs in the small 
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intestine by immunohistochemistry and revealed that there were no significant differences in the number of CD11c ϩ DCs and CD11c ϩ CD86 ϩ mature DCs between the 2 groups ( Figure 3E ). However, the percentage of CD86 ϩ cells in CD11c ϩ DCs was lower in the calcitriol group.
Effects of Calcitriol on Tregs, DCs, and Inflammatory Cells in Atherosclerotic Plaques
To evaluate the effects of calcitriol on Tregs and DCs in atherosclerotic plaques, we conducted immunohistochemical studies and RT-PCR in atherosclerotic lesions. The immunohistochemical analyses of Foxp3 ϩ Tregs in atherosclerotic lesions showed a significantly increased number of Foxp3 ϩ Tregs in the calcitriol group (PϽ0.05, Figure 4A and 4B). We further examined the expression of Treg-associated markers, such as CD25, Foxp3, and CTLA4, in atherosclerotic lesions and demonstrated that mRNA levels of all Treg-associated markers significantly increased in the calcitriol group when compared with the control group (PϽ0.05, Figure 4C ). Recent studies have suggested that antigen presentation may occur within atherosclerotic plaques and in lymphoid organs and that Tregs migrate to atherosclerotic lesions to suppress local immune responses. 25 Our finding supports this notion and implies that Tregs could be a promising target in treating atherosclerotic plaques. Next, we investigated the effect of calcitriol on DCs in atherosclerotic lesions and found that the numbers of CD11c ϩ DCs and CD11c ϩ CD86 ϩ mature DCs and the percentage of CD86 ϩ cells among CD11c ϩ DCs were significantly decreased in the calcitriol group (PϽ0.05, Figure 4D and 4E). These results indicated that calcitriol decreased the number of DCs recruited into the plaque and that they were maintained in an immature state in atherosclerotic lesions. To reveal the effects of oral calcitriol treatment on inflammatory cells, such as macrophage and CD4 ϩ cells, we conducted immunohistochemical studies of the atherosclerotic lesions ( Figure 4F and 4G) . Interestingly, the 200-ng calcitriol group showed a 29.0% reduction in the accumulation of macrophages (PϽ0.01) and also a 26.4% decrease in CD4 ϩ T-cell infiltration (Pϭ0.02), compared with the values recorded for the control group.
Next, to reveal the mechanisms of reduced atherosclerotic plaque development and inflammatory cell recruitment, we examined mRNA expression of the proinflammatory molecules in atherosclerotic plaques by quantitative RT-PCR ( Figure 4H ). We found that adhesion molecule and proinflammatory chemokine and cytokine, such as vascular cell adhesion molecule-1, monocyte chemoattractant protein-1, and interferon-␥, were markedly reduced (PϽ0.05) and that anti-inflammatory cytokines, such as TGF-␤ and IL-10, were significantly increased (PϽ0.05) in the calcitriol group when compared with the control group. The expression of DCderived chemokine CCL22 mRNA was significantly increased (PϽ0.05); and the expression of its receptor, CCchemokine receptor (CCR) 4, tended to increase in atherosclerotic lesions of the calcitriol group (Pϭ0.0983).
Taken together, these results indicated that calcitriol might inhibit the migration of effector T cells and macrophages into the plaques by increasing the proportion of immature DCs and Tregs systemically and locally in atherosclerotic plaques.
Inhibition of Tregs by Injection of Neutralizing Anti-CD25 Antibodies
To clarify the interaction between Tregs and DCs in preventing atherosclerosis after calcitriol treatment, we conducted an in vivo CD25 neutralization study with the injection of anti-CD25 antibody. According to a previous report, 9 the effect of a single intraperitoneal injection of 100 g of CD25-depleting PC61 antibody was maintained for 4 weeks. In our experiment, we injected CD25-depleting PC61 antibody or isotype-matched control antibody into mice once every 4 weeks at the ages of 6, 10, and 14 weeks. Both the calcitriol and control groups receiving anti-CD25 antibody showed significantly increased atherosclerotic lesion formation when compared with the calcitriol group receiving isotype-matched control antibody (PϽ0.05, Figure 5A ). These results suggested that Tregs had pivotal and major roles in inhibiting atherosclerosis after calcitriol treatment. Notably, when mice were injected with neutralizing antibody, there remained significant differences in atherosclerotic lesion formation between calcitriol-treated and control mice, indicating that calcitriol partially inhibited atherosclerotic lesion formation independent of Tregs (PϽ0.05). We also measured the percentage of Tregs by FACS in the MLNs and spleens after the injection of anti-CD25 antibody ( Figure  5B-5E ). In contrast with a previous report, 9 we observed a 60% to 80% depletion in CD4 ϩ CD25 ϩ Tregs and CD4 ϩ CD25 ϩ Foxp3 ϩ Tregs in MLNs and spleens at 1 week after a single intraperitoneal injection of 100 g of CD25-depleting PC61 antibody. However, all changes had reversed by 2 weeks after injection (supplemental Figure II) .
We further analyzed DC maturation after partial depletion of CD4 ϩ CD25 ϩ Tregs and observed that the rates of maturation were increased by anti-CD25 antibody administration and that the calcitriol group receiving anti-CD25 antibody still showed a decrease in the number of CD80 ϩ CD86 ϩ mature DCs when compared with the control group receiving anti-CD25 antibody injection ( Figure 5F ). These data suggest that DC maturation was highly associated with the induction of Tregs, although calcitriol may partially decrease DC maturation independent of Tregs. It is likely that calcitriol mainly inhibits the progression of atherosclerosis via a Treg-dependent pathway but also a partly DC-mediated and Treg-independent manner.
Discussion
Recent clinical studies and experimental investigations have indicated that vitamin D 3 insufficiency increases the inci- Although the antiatherogenic mechanism of Tregs' effect and the functional role of DCs in atherogenesis still remain to be determined, we have revealed, for the first time to our knowledge, that calcitriol-induced tolerogenic DCs and Tregs might have antiatherogenic properties. Accumulating evidence has revealed that several subsets of Tregs have beneficial effects on atherogenesis. 9 -12 Both naturally occurring CD4 ϩ CD25 ϩ Tregs and IL-10 -producing Tregs (Tr1) have inhibited atherosclerosis in mouse models. 10, 11 Recently, it was demonstrated that an orally administrated immunomodulatory agent, anti-CD3 antibody, inhibits atherosclerosis by inducing Tregs, especially latencyassociated peptide Tregs. 12 Vitamin D 3 receptor (VDR) ligands induce the differentiation of Foxp3 ϩ Tregs 18 and Tr1 in the presence of dexamethasone, 26 and both types of Tregs contribute to T-cell immune response inhibition. In the present study, FACS analyses in MLNs and spleens documented that Foxp3 ϩ Tregs were significantly increased in the calcitriol group. However, it is unlikely that Tr1 and latencyassociated peptide Tregs play central roles in Treg induction by calcitriol (supplemental Figure III) . Foxp3 ϩ Tregs were significantly increased in systemic lymphoid organs and atherosclerotic lesions in the calcitriol group. Although the actual roles of intraplaque Tregs in atherogenesis have not yet been clarified, a previous study suggested that increasing numbers of Tregs might suppress pathogenic T-cell immune responses or macrophage activation in atherosclerotic lesions. 12 Several articles have previously reported that VDR ligands inhibit the differentiation and maturation of DCs. 18 -21 These results included the observation that treatment of DCs with calcitriol leads to low surface expression of costimulatory molecules, such as CD80 and CD86; decreased IL-12 production; and enhanced secretion of IL-10 and CCL22, resulting in T-cell hyporesponsiveness. The presence of such costimulatory molecules on DCs is required for T-cell activation and for differentiation from naïve T lymphocytes into effector T cells. In the absence of costimulation, T cells interacting with DCs undergo anergy or apoptosis. IL-12p70, a heterodimeric cytokine consisting of p35 and p40, is released mainly by activated macrophages and DCs. IL-12p70 is a key mediator in inducing T-helper type 1 response and stimulates the production of interferon-␥ from T-helper type 1. Inhibition of DC-derived IL-12p70 production is followed by a downregulated response of T-helper type 1. Furthermore, the anti-inflammatory cytokine IL-10 also inhibits T-cell immune response by acting on antigen-presenting cells, such as macrophages and DCs. Our FACS analysis revealed that CD80 ϩ CD86 ϩ DCs are decreased in MLNs and spleens of calcitriol-treated mice, indicating augmentation of the immature DC phenotype. Expression of IL-12p40 mRNA in splenic DCs was decreased, and expression of IL-10 was increased. We clearly demonstrated that DCs from the calcitriol treatment group had less T-cell proliferation activity, which might indicate that DCs changed their phenotypes to tolerogenic. Recently, the functional importance of DCs in atherosclerosis has been highlighted in several animal and human studies. [15] [16] [17] Accumulating evi-dence suggests that DCs in atherosclerosis are involved in antigen presentation to T cells within plaques. 15 DCs present in normal arteries are immature and become activated during atherogenesis, and DCs in vessels have been involved in the initiation and progression of atherosclerosis. 16, 17 Regarding the interactions between Tregs and tolerogenic DCs, immature DCs lacking sufficient expression of costimulatory molecules have induced Tregs 13, 14 and affected suppressive immunoresponses through the induction of antiinflammatory cytokines, such as IL-10 27 and TGF-␤. 28 In our study, we demonstrated that expression of IL-10 mRNA in DCs was significantly increased, whereas expression of TGF-␤ mRNA was not increased. In accordance with previously published findings that naïve T cells in the periphery can differentiate into Foxp3 ϩ Tregs in the presence of IL-10, 29 the increase of IL-10 in tolerogenic DCs might contribute to the induction of Tregs, including Tr1. Tregs play critical roles in the differentiation of immature DCs through the interaction of CTLA4 and CD80/CD86. Tregs constitutively express high levels of CTLA4 that bind to CD80 and CD86 with high affinity. CTLA4 activity is important for Treg-induced tolerance in several animal models. 30 The interaction of CTLA4 on Tregs with CD80/CD86 on CD11c ϩ DCs conveyed a negative signal to DCs and reduced the expression of these costimulatory molecules on DCs in vitro. 31 In our study, CTLA4 mRNA expression in CD4 ϩ T cells was significantly increased in the calcitriol group. Taken together, we conclude that Tregs and tolero- 
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genic DCs might interact via CTLA4 and CD80/CD86 to induce each other, resulting in effective inhibitory immunoresponses in both cell types. We also found another important interaction between Tregs and tolerogenic DCs: expression of CCL17 and CCL22 mRNA in the splenic DCs was enhanced in the calcitriol group in this study. These chemokines are ligands for CCR4 and CCR8 expressed on Tregs. 32 DCs are the major source of CCL22 in vitro and in vivo, 33 and transcriptional changes and production of CCL22 in human myeloid DCs have been induced by calcitriol. 23, 24 In the present study, calcitriol increased CCL22 expression in DCs, suggesting that DCs released Treg-attracting chemokines and attracted Tregs via CCR4. Tregs were also promoted in vivo by calcitriol administration. In addition, the percentage of immature DCs was increased in atherosclerotic lesions in the calcitriol group. Interestingly, the expression of CCL22 mRNA was significantly increased and its chemokine, CCR4, tended to increase in atherosclerotic lesions of the calcitriol group. It is likely that tolerogenic DCs release CCL22 to interact with CCR4-expressing Tregs in spleen and within atherosclerotic plaques; thus, DCs may function as antiatherogenic agents.
To clarify the roles of Tregs in the antiatherogenic effects of calcitriol and DC maturation, we examined the effect of CD25-neutralizing monoclonal antibody. Tregs characteristically express Foxp3 and, in most cases, CD25. Functional studies in which CD4 ϩ CD25 ϩ Tregs were depleted with anti-CD25 antibodies in ApoE Ϫ/Ϫ mice resulted in an increase of atherosclerotic lesions. 9 In contrast to the previous study, in our model, Tregs were not completely deleted by anti-CD25 antibodies after 4 weeks; however, partial inhibition of Tregs by injection of anti-CD25 antibodies partially reversed the beneficial effects of calcitriol on atherogenesis and slightly increased DC maturation at 1 week after anti-CD25 antibody injection. These data suggest that Tregs induced by oral calcitriol administration may have an important role in inhibiting atherogenesis and that calcitriol directly decreased DC maturation and inhibited the progression of atherosclerosis, independent of Tregs; however, partly immature DCs were induced via a Treg-dependent pathway.
In the present study, oral administration of calcitriol definitely regulated and affected the function and proportion of DCs and Tregs in MLNs and reduced atherosclerotic lesion formation. It is likely that modulation of both intestinal and systemic immune systems is critical to calcitriol-induced antiatherogenic properties. In a previous article, it was reported that oral administration of anti-CD3 antibody induced latency-associated peptide T cells in MLNs and spleens. 12 We also confirmed that the maturation of DCs was inhibited and that the proportion of CD11c ϩ CD80 Ϫ CD86 Ϫ DCs in MLNs was increased at the same time, suggesting that an orally administered small amount of antibody reached the intestine (but not in the blood), possibly regulated intestinal immunity, and resulted in the mutual differentiation of tolerogenic DCs and Tregs in MLNs (N.S., unpublished data). In the present study, we demonstrated that oral calcitriol administration increased the number of Tregs in MLNs but not in the thymus (supplemental Figure I) . Taken together, although we should be careful about the interpretation of our results, the intestinal immune system might be a novel therapeutic target for treatment of CVDs and atherosclerosis. This possibility must be further investigated.
In summary, we have demonstrated that oral administration of the active form of vitamin D 3 inhibits atherosclerosis development by inducing tolerogenic DCs and Tregs. We report herein, for the first time to our knowledge, that Tregs and tolerogenic DCs work as antiatherogenic agents and that both cells may play key roles in the beneficial effects of calcitriol on atherogenesis. It is likely that tolerogenic DCs recruit Tregs through chemokine CCL22 and its receptor, CCR4; both cells interact through the cell-to-cell contact of CTLA4 and CD80/CD86 at lymphoid organs and atherosclerotic lesions. These data indicate that calcitriol could be used clinically as a promising therapy for preventing atherosclerotic CVD. Clinical studies in humans are required to identify the efficacy of oral calcitriol in the prevention of atherosclerotic diseases and to evaluate the relationship between plasma levels of calcitriol and CVDs. 
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